drugset / Trial / NCT00373360

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

NCT00373360

Phase 4 Completed 10 enrolled United Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.

Timeline

Start
2006-09
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified Intravenous